Dr Vinay Prasad was appointed as director of the Centre for Biologics Evaluation and Research in May, but he stepped down ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

Dr. Vinay Prasad is back at the FDA less than two weeks after the White House pressed the head of the agency to remove him from his multiple agency leadership roles, an HHS spokesperson said Saturday.

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

Scientists have found that lithium orotate — which is different from the kind of lithium typically used to treat mental health conditions — not only stopped the brain disease in mice but also reversed ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...